Immunotherapy News and Research

Latest Immunotherapy News and Research

New method to target, eliminate cancer-supporting macrophages in mouse tumors

When a person has cancer, some of the cells in his or her body have changed and are growing uncontrollably. Most cancer drugs try to treat the disease by killing those fast-growing cells, but another approach called immunotherapy tries to stimulate a person's own immune system to attack the cancer itself.

17 Sep 2013

Neostem Licenses UCSF Patents Covering Methods For "Tregs"

...

16 Sep 2013

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics AG and The Leukemia & Lymphoma Society today announced a partnership to co-fund a phase 2 trial with the Recruit-TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma patients for whom currently available treatments have failed.

16 Sep 2013

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Scientists from A*STAR's Singapore Immunology Network have discovered a new defense mechanism that the immune system utilises to combat infections. The team's discovery of how a novel protein unexpectedly activates an immune response shows how this mechanism can also be used to get rid of tumour cells.

11 Sep 2013

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

...

10 Sep 2013

Roche Signs Up To $422.5M Collaboration With Inovio

...

10 Sep 2013

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Roche and Inovio Pharmaceuticals, Inc. announced today that they have entered into an exclusive worldwide license agreement to research, develop and commercialize Inovio's highly-optimized, multi-antigen DNA immunotherapies targeting prostate cancer and hepatitis B.

10 Sep 2013

Myeloid derived suppressor cells provide niche where cancer stem cells survive

The immune system is normally known for protecting the body from illness. But a subset of immune cells appear to be doing more harm than good.

6 Sep 2013

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

A study published today in Aging Cell identifies a new tool to accurately analyze extremely rare mitochondrial DNA deletions associated with a range of diseases and disorders as well as aging. This approach, which relies on Droplet Digital PCR (ddPCR-) technology, will help researchers explore mtDNA deletions as potential disease biomarkers.

4 Sep 2013

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Apitope, the drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion with positive results of its second Phase I clinical trial of ATX-MS-1467.

3 Sep 2013

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Imaxio, a biopharmaceutical company specializing in vaccines and genomics, announces today that IMX313, its proprietary pro-immunogenic technology, has been administered for the first time in humans in a tuberculosis vaccine phase I clinical study. The trial is being conducted by the Jenner Institute at Oxford University, England.

3 Sep 2013

Women in their 40s and 50s are hospitalized more than twice for asthma attack

Asthma is a disease that mostly affects young boys and adult women. And according to a new study, women in their 40s and 50s with asthma are hospitalized more than twice as often as men in the same age group. The 10-year study is published in the September issue of Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology (ACAAI).

3 Sep 2013

ddPCR technology can be used to reproducibly quantify microRNA in plasma

A study published online in Nature Methods today demonstrated that Droplet Digital PCR (ddPCR-) technology can be used to precisely and reproducibly quantify microRNA (miRNA) in plasma and serum across different days, paving the way for further development of miRNA and other nucleic acids as circulating biomarkers.

2 Sep 2013

LLS survey uncovers alarming lack of knowledge among U.S. adults about blood cancers

Less than one half (46%) of adults polled in a new survey believe that blood cancers are one of three leading causes of cancer death in the U.S. In fact, blood cancers are the third leading cause of cancer death, behind cancers of the respiratory system, including lung cancer, and cancers of the digestive system, including colorectal cancer.

30 Aug 2013

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

A team of researchers led by Janet Stanford, Ph.D., of Fred Hutchinson Cancer Research Center has discovered that mutations in the gene BTNL2, which encodes a protein involved in regulating T-cell proliferation and cytokine production - both of which impact immune function - increase the risk of developing prostate cancer.

30 Aug 2013

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Coffee consumption is associated with a lower risk of prostate cancer recurrence and progression, according to a new study by Fred Hutchinson Cancer Research Center scientists that is online ahead of print in Cancer Causes & Control.

27 Aug 2013

Seven researchers to receive grants from ASTRO to advance radiation oncology research

The American Society for Radiation Oncology (ASTRO) has selected seven (7) leading researchers who will receive a total of $675,000 in awards and grants to advance radiation oncology research.

23 Aug 2013

Novel Approach Developed On Antitumor Immunotherapy

...

22 Aug 2013

New type of cancer immunotherapy harnesses body's immune system to attack tumors

By carefully adjusting the function of crucial immune cells, scientists may have developed a completely new type of cancer immunotherapy—harnessing the body's immune system to attack tumors. To accomplish this, they had to thread a needle in immune function, shrinking tumors without triggering unwanted autoimmune responses.

19 Aug 2013

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Advaxis, Inc., (OTCQB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.

17 Aug 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

New method to target, eliminate cancer-supporting macrophages in mouse tumors

Neostem Licenses UCSF Patents Covering Methods For "Tregs"

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Discovery opens doors for developing new therapies to eradicate tumor cells, combat infections

Bayer, Broad On Five-Year Mission To Search For Novel Cancer Therapeutics

Roche Signs Up To $422.5M Collaboration With Inovio

Roche, Inovio Pharmaceuticals to develop DNA-based vaccines for prostate cancer and hepatitis B

Myeloid derived suppressor cells provide niche where cancer stem cells survive

Study identifies new tool to accurately analyze mtDNA deletions associated with diseases, aging

Apitope successfully completes ATX-MS-1467 Phase I trial in relapsing MS patients with positive results

Imaxio's pro-immunogenic technology used in tuberculosis vaccine phase I clinical study

Women in their 40s and 50s are hospitalized more than twice for asthma attack

ddPCR technology can be used to reproducibly quantify microRNA in plasma

LLS survey uncovers alarming lack of knowledge among U.S. adults about blood cancers

BTNL2 gene mutation that impacts immune function increases risk of prostate cancer

Bioactive compounds in coffee may prevent prostate cancer recurrence, delay progression

Seven researchers to receive grants from ASTRO to advance radiation oncology research

Novel Approach Developed On Antitumor Immunotherapy

New type of cancer immunotherapy harnesses body's immune system to attack tumors

FDA grants Orphan Drug Designation to ADXS-HPV for treatment of HPV-associated anal cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Immunotherapy News and Research

Latest Immunotherapy News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in